文献速递心力衰竭与心肌病

非奈利酮在心力衰竭中的估计长期获益:FINEARTS-HF随机临床试验的预设二次分析

Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究为FINEARTS-HF试验的预设二次分析,纳入6001例LVEF≥40%的症状性心衰患者,随机接受非奈利酮或安慰剂,中位随访2.6年。采用基于年龄的Kaplan-Meier曲线估计终生无事件生存获益,结果显示55岁患者无事件生存期延长3.1年(95%CI 0.8-5.4),65岁患者延长2.0年(95%CI 0.8-3.3),且在各起始年龄及已使用SGLT2抑制剂者中均观察到获益。

要点

  • 非奈利酮可延长HFmrEF/HFpEF患者无事件生存期,55岁者估计延长3.1年。
  • 65岁患者估计延长2.0年,50-80岁各起始年龄均显示数值上更优。
  • 已使用SGLT2抑制剂者仍可获益,65岁者估计延长3.1年(95%CI 0.1-6.0)。

核心结论

  • 在HFmrEF/HFpEF患者中,长期使用非奈利酮估计可将无事件生存期延长最多3年。

研究设计与样本

  • FINEARTS-HF试验的预设二次分析,该试验为3期随机临床试验,在37个国家653个中心开展。
  • 纳入6001例40岁及以上、有症状且LVEF≥40%的心衰患者,2020年9月至2023年1月随机分组,中位随访2.6年(IQR 1.9-3.0)。
  • 干预为非奈利酮(滴定至20mg或40mg)或安慰剂。

主要发现

  • 55岁患者平均无事件生存期:非奈利酮组13.6年(95%CI 11.9-15.2),安慰剂组10.5年(95%CI 6.8-11.3),延长3.1年(95%CI 0.8-5.4;P=.007)。
  • 65岁患者平均无事件生存期:非奈利酮组11.0年(95%CI 10.1-11.9),安慰剂组8.9年(95%CI 8.1-9.8),延长2.0年(95%CI 0.8-3.3;P=.001)。
  • 50至80岁各起始年龄的非奈利酮组估计平均无事件生存期均数值上高于安慰剂组。
  • 已使用SGLT2抑制剂者中,65岁患者估计延长3.1年(95%CI 0.1-6.0;P=.04)。

临床怎么用

  • 对于HFmrEF/HFpEF患者,可基于长期无事件生存获益的估计与患者共同决策非奈利酮的使用。
  • 即使患者已接受SGLT2抑制剂治疗,仍可考虑加用非奈利酮以进一步改善长期预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: People living with heart failure (HF) with mildly reduced or preserved ejection fraction have substantially curtailed life expectancy free from clinical events compared with their peers of comparable age. The nonsteroidal mineralocorticoid receptor antagonist, finerenone, was recently shown to reduce risks of cardiovascular events in this population over a median follow-up of 2.6 years; as patients with HF typically continue treatment beyond this time frame, estimating the potential long-term benefits of finerenone could inform shared clinical decision-making. OBJECTIVE: To estimate the projected long-term treatment effects of finerenone in patients with HF with mildly reduced or preserved ejection fraction if treated over a patient's lifetime. DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted of the FINEARTS-HF trial, a phase 3 randomized clinical trial conducted across 653 sites in 37 countries. Adults 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater were randomized from September 2020 to January 2023. Median (IQR) follow-up was 2.6 (1.9-3.0) years. INTERVENTIONS: Finerenone (titrated to either 20 mg or 40 mg) or placebo. MAIN OUTCOMES AND MEASURES: The primary composite outcome was time to cardiovascular death or worsening HF event. The long-term gains in survival free from a primary end point with finerenone were iteratively estimated with age-based Kaplan-Meier curves using age at randomization rather than time from randomization. Differences in areas under the survival curves between the finerenone and placebo arms represented event-free survival gains. RESULTS: Among 6001 participants (median [IQR] age, 73 [66-79] years; 3269 male [54.5%]), mean survival free from the primary end point for a 55-year-old participant was 13.6 years (95% CI, 11.9-15.2 years) with finerenone and 10.5 years (95% CI, 6.8-11.3 years) with placebo, representing a gain in event-free survival of 3.1 years (95% CI, 0.8-5.4 years; P = .007). Mean event-free survival for a 65-year-old participant was 11.0 years (95% CI, 10.1-11.9 years) with finerenone and 8.9 years (95% CI, 8.1-9.8 years) with placebo, representing a gain of 2.0 years (95% CI, 0.8-3.3 years; P = .001). Projected mean event-free survival was numerically greater with finerenone than with placebo for every starting age between 50 to 80 years. Lifetime gains in event-free survival were observed even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor (65-year-old participant: 3.1 years; 95% CI, 0.1-6.0 years; P = .04). CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Vaduganathan, Claggett, Desai, et al. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 39332395. doi:10.1001/jamacardio.2024.3782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。